Aziyo Biologics, Inc., announced today the launch of OsteGro, an allograft bone matrix that supports new bone growth in orthopedic surgical procedures. The launch of OsteGro further expands the company’s bone repair franchise.
Darryl Roberts, Ph.D., General Manager, Strategic Tissue Partnerships at Aziyo said, “We are excited to add OsteGro to our innovative orthopedic surgery product line. OsteGro represents the third product in our portfolio which already includes ViBone, a viable bone matrix, and OsteSpine, a complete line of precision machined cervical spacers.” He concluded, “Our goal is to build an industry leading franchise in biologic materials for orthopedic surgery. This launch is yet another step towards that goal.”
OsteGro is an allograft bone matrix developed with Aziyo’s proprietary processing methods that results in a bone graft that serves as a scaffold for new bone growth. Because OsteGro can be stored at room temperature, it is ready for immediate use in a wide range of surgical procedures. Bone repair allografts like OsteGro are used in procedures such as spinal fusion, hip reconstruction and bone fractures. OsteGro is part of the growing biologics segment of U.S. orthopedic market. This segment alone is estimated to total approximately $2 billion in annual sales.